MDLN — Stock Film
STOCK FILMSCENE 1/11MDLN · $32.58
Stock Expert AI presents
MDLN
Medline Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Medline Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 45,000 employees. Now — the numbers.

on the stock market since 2025
45K employees
$33B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $4 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 4%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 10% a year over the last 3 years. Red columns mark years that ended in a loss.

$21B
2022
$23B
2023
$26B
2024
$28B
2025
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $10.6B. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
74
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
50
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
86
very strong

The price looks reasonable next to what the company earns.

GROWTH
78
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
29
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 35% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 10% a year on average.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $46.3342% above today’s price.

1
THE RISKS · 1/3
Executives lean toward selling

Over the last 12 months, executives reported 30 sells against just 7 buys. Not an alarm bell by itself, but a number worth watching.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 29/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
Costs eat into the margin

Costs swallow the gains that sales growth brings in. Council score: 4/10.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, MDLN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: MDLN is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film